Imunoexpressão do receptor do fator de crescimento epidérmico (EGFR) nos tecidos neoplásicos e adjacentes do carcinoma colorretal esporádico

Barra lateral de artigos

PDF
Publicado: abr 30, 2012
DOI: https://doi.org/10.7322/abcs.v37i1.42
Palavras-chave:
Genes erbB-1, fator de crescimento epidérmico, marcadores biológicos, imunoistoquímica, carcinoma, neoplasias colorretais

Conteúdo do artigo principal

Bianca Doimo Sousa
Curso de Medicina da Faculdade de Medicina do ABC (FMABC) – Santo André (SP), Brasil.
Maurício Andrade Azevedo
Serviço de Gastroenterologia Cirúrgica do Conjunto Hospitalar do Mandaqui – São Paulo (SP), Brasil.
Ana Maria Amaral Antonio Mader
Disciplina de Patologia da FMABC – Santo André (SP) Brasil.
Lourdes Conceição Martins
Programa de Pós-graduação em Saúde Coletiva da Universidade Católica de Santos (UNISANTOS) – Santos (SP), Brasil.
Jaques Waisberg
Disciplina de Cirurgia do Aparelho Digestivo da FMABC – Santo André (SP), Brasil; Serviço de Gastroenterologia Cirúrgica do Hospital do Servidor Público Estadual (IAMSPE) – São Paulo (SP), Brasil.

Resumo

Introdução: O estudo da imunoexpressão tecidual do receptor do fator de crescimento epitelial (EGFR) pode contribuir para o entendimento de seu papel no prognóstico do carcinoma colorretal. Objetivo: Analisar a expressão imuno-histoquímica do EGFR no carcinoma colorretal e nos tecidos da transição tumor-mucosa e da mucosa adjacente à neoplasia. Métodos: Em 40 pacientes com carcinoma colorretal operados com intenção curativa, estudou-se a imunoexpressão do EGFR com anticorpo monoclonal anti-EGFR. Foram utilizados testes paramétricos e não paramétricos. Resultados: A imunoexpressão do EGFR nas amostras de tumor apresentou diferença significante em relação ao nível de imunoexpressão em espécimes de tecido da transição tumor/mucosa (p=0,01) e no nível de imunoexpressão em tecidos da mucosa adjacente (p=0,04). Conclusão: O EGFR apresentou maior imunoexpressão na mucosa do carcinoma colorretal em comparação à expressão no epitélio de transição e na mucosa adjacente não neoplásica.

Detalhes do artigo

Edição
v. 37 n. 1 (2012)
Seção
Artigos Originais

Referências

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer Statistics; 2006. CA Cancer J Clin. 2006;56(2):106-30. http://dx.doi.org/10.3322/canjclin.56.2.106

American Cancer Society [Internet]. Global Cancer Facts & Figures 2007. [cited 2011 Jul 08]. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf

Louvet C, Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001;91(11):2033-8. http://dx.doi.org/10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J

Midgley RS, Kerr DJ. Adjuvant treatment of colorectal cancer. Cancer Treat Rev. 1997;23(3):135-52. http://dx.doi.org/10.1016/S0305-7372(97)90035-9

Sobrero A, Guglielmi A. Current controversies in the adjuvant therapy of colon cancer. Ann Oncol. 2004;15(Suppl 4):iv39-41.

Zaniboni A, Labianca R. Grupo italiano per lo studio e la cura dei tumori del digerente. Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol. 2004;15(9):1310-8. http://dx.doi.org/10.1093/annonc/mdh342

Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Glosh N, et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum. 2001;44(4):523-33. http://dx.doi.org/10.1007/BF02234324

Waisberg J, Landman G, Cha ASH, Henriques AC, Gaspar HA, Speranzini MB. Padrão da distribuição tecidual do CEA no carcinoma colo-retal: relação com o nível sérico do CEA e classificação de Dukes. Rev Bras Colo-Proctol. 2002;22(1):20-6.

Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55(2):138-42.

Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res. 2006;12(4):1184-91. http://dx.doi.org/10.1158/1078-0432.CCR-05-1864

Galizia G, Lieto E, Ferraracio F, Orditura M, Vita F, Castellano P, et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res. 2004;10(10):3490-9 http://dx.doi.org/10.1158/1078-0432.CCR-0960-03

Bukeirat FA, Ostrinsky Y, McFadden D. Use of GI tumor markers in clinical practice: a practical interpretation. W V Med J. 2008;104(4):17-21.

Duffy MJ, Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-60. http://dx.doi.org/10.1016/j.ejca.2007.03.021

Daniels IR, Fisher SE, Heald RJ, Moran BJ. Accurate staging, selective preoperative therapy and optimal surgery improves outcome in rectal cancer: a review of the recent evidence. Colorectal Dis. 2007;9(4):290-301. http://dx.doi.org/10.1111/j.1463-1318.2006.01116.x

Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007;176:61-80 http://dx.doi.org/10.1007/978-3-540-46091-6_7

Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 2011;12(66):419-32.

Grossmann AH, Samowitz WS. Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. Arch Pathol Lab Med. 2011;135(10):1278-82. http://dx.doi.org/10.5858/arpa.2011-0047-RA

Enrique AA, Gema PC, Jeronimo JC, Auxiliadora GE. Role of anti-EGFR target therapy in colorectal carcinoma. Front Biosci. 2012;4:12-22. http://dx.doi.org/10.2741/E357

Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, et al. Distribution and fuction of EGFR in human tissue and the effect of EGRF tyrosine kinase inibition. Anticancer Res. 2003;23(5A):3639-50.

Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102(I):37-46. http://dx.doi.org/10.1016/j.pharmthera.2004.01.002

Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787-99. http://dx.doi.org/10.1200/JCO.2003.01.504

Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002;99(3):1521-6. http://dx.doi.org/10.1073/pnas.032678499

Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SP, et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc (Min/+) mice. Mol Cancer Ther. 2008;7(3):590-8. http://dx.doi.org/10.1158/1535-7163.MCT-07-0433

Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007;13(12):527-34. http://dx.doi.org/10.1016/j.molmed.2007.10.002

Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7(10):2958-70.

Goldstein NS, Armin M, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92(5):1331-46. http://dx.doi.org/10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M

Spano JP. Lagorce C, Atlan D, Milano G, Domont J, Benamouzing R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1):102-8. http://dx.doi.org/10.1093/annonc/mdi006

Italiano A, Saint-Paul MC, Caroli-Bosc FX, François E, Bourgeon A, Benchimol D, et al. Epidermal growth factor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol. 2005;16(9):1503-07. http://dx.doi.org/10.1093/annonc/mdi282

Khalifa MA, Rowsell CH, Gladdy RA, Ko YJ, Hanna S, Smith A, et al. Expression of epidermal growth factor receptor in primary colorectal adenocarcinoma predicts expression in recurrent disease. Am J Clin Pathol. 2006;125(2):229-33. http://dx.doi.org/10.1309/HV7V1MJXV8Y8989W

Bralet MP, Paule B, Falissard B, Adam R, Guettier C. Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology. 2007;50(2):210-6. http://dx.doi.org/10.1111/j.1365-2559.2007.02578.x

Scartozzi M, Bearzi I, Bearzi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implication for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22(23):4772-8. http://dx.doi.org/10.1200/JCO.2004.00.117

Galizia G, Lieto E, Ferraraccio F, Vita F, Castellano P, Orditura M, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol. 2006;13(6):823-35. http://dx.doi.org/10.1245/ASO.2006.05.052

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecam in irinotecanrefractory metastatic colorectal câncer. N Engl J Med. 2004;351(4):337-45. http://dx.doi.org/10.1056/NEJMoa033025

Overman MJ, Hoff PM. EGFR-target therapies in colorectal cancer. Dis Colon Rectum. 2007;50(8):1259-60. http://dx.doi.org/10.1007/s10350-007-0228-3

Doger FK, Meteoglu I, Tuncyurek P, Okyay P, Cevikel H. Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res. 2006;38(6):540-4. http://dx.doi.org/10.1159/000096774

Spindler KL, Lindebjerg J, Nielsen JN, Olsen DA, Bisgard C, Brandslund I, et al. Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods. Int J Oncol. 2006;29(5):1159-65.

Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160-74. http://dx.doi.org/10.1056/NEJMra0707704

Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 2006;12(3):229-36. http://dx.doi.org/10.1097/00130404-200605000-00012

Karameris A, Kanavaros P, Aninos D, Gorgoulis V, Mikou G, Rokas T, et al. Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases. Pathol Res Pract. 1993;189(2):133-7. http://dx.doi.org/10.1016/S0344-0338(11)80082-8

Baiocchi G, Lopes A, Couldry RA, Rossi BM, Soares FA, Aguiar S, et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis. 2009;24(9):1059-68. http://dx.doi.org/10.1007/s00384-009-0702-6